Neurosoft raised a $7.5M seed round to advance soft cortical BCIs, pairing Swiss neuroengineering roots with US investors, clinical trials, and Science Corp’s BCI infrastructure.

SonoMind raised €20 million to advance a focused ultrasound treatment for depression, testing whether non-invasive deep brain targeting can become a clinical option for treatment-resistant patients.

Motif’s FDA IDE moves its depression implant into first clinical testing, while its MintNeuro partnership highlights the chip-level constraints behind smaller therapeutic BCIs.

Europe’s first Brain Economy Summit framed brain capital as an economic asset. The harder question is whether Europe can turn neuroscience, policy, and funding into scalable systems.

Axoft’s $55M Series A highlights a growing focus on implant materials in BCI, as companies work to improve tissue compatibility, signal quality, and the durability needed for clinical translation.

Sabi has emerged from stealth with a claimed thought-to-text EEG beanie, testing whether high-density sensors and AI can push consumer neurotech beyond metrics and into usable neural input.

April brought a cluster of neural interface updates across cortical, spinal, endovascular, peripheral, and materials-led systems, showing progress beyond a single BCI product model.

INBRAIN has completed enrolment in its first human graphene cortical interface study, adding safety and signal-quality data to its broader push around materials-led BCI development.

Synchron’s INTENT trial marks a new stage in its clinical translation, as the company pairs endovascular BCI development with reimbursement, software, and platform integration work.

CFG’s new white paper signals a more coordinated EU approach to neurotechnology, centered on funding gaps, regulatory clarity, and the unresolved boundary between wellness and medicine.

Epia Neuro has emerged from stealth with a minimally invasive BCI for stroke recovery. Its launch adds to a more active BCI market, where capital and competitive pressure are both rising.

Rune Labs has launched a Parkinson’s AI companion built on years of wearable-derived patient data. The move highlights how cleared neurotech tools can turn clinical monitoring into a longer-term data advantage.

Theta Neuro has raised a $2m pre-seed to advance a wearable EEG patch for seizure prediction. The broader question is whether non-invasive forecasting can become a credible epilepsy product category.

Neurable used EEG-enabled hearing protection to record brain activity during live breaching drills. The dataset points to short-window neural changes that standard post-event assessment can miss.

Cognito’s Ochsner deal sits further along a broader shift in neurotech partnerships, from invasive research sites to translational collaborators and now care-system integration.

The Declaration of Sydney outlines an ethical framework for computational neurosurgery, with wider implications for oversight, enhancement, and neurotech governance.

China’s BCI strategy is starting to produce commercial milestones. A first approved therapeutic device and Gestala’s launch point to a broader competitive field across invasive and non-invasive systems.

Cognito Therapeutics has raised $105 million to advance its gamma-entrainment headset through Phase 3 in Alzheimer’s. The financing sharpens attention on whether biological signals can translate into clinical benefit.

Temple has raised $54 million to build a brain wearable for athletes. The question is whether cerebral hemodynamic sensing can become a useful performance layer.

Science closed an oversubscribed $230M Series C, taking total raised to ~$490M, to commercialize PRIMA in Europe, expand trials into Stargardt and RP, and scale manufacturing and clinical ops in 2026.

Clee Medical raised Seed funding for Neuro Access, an OCT-based tool that brings contrast-free real-time imaging to stereotactic neurosurgery, aiming to reduce uncertainty from brain shift in theatre.

Neuralink files an $8.2M Austin renovation as it builds manufacturing capacity, following a 144,000 sq ft South San Francisco lease. The moves align with stated 2026 production goals.

Brainlab and Precision NeuroMed will co-develop CED planning software, combining imaging workflows with flow simulation to improve procedure consistency across sites. Initial focus is glioblastoma.

Neurosoft Bioelectronics will use Science Corp’s BCI “Ecosystem” stack to speed full-system development. The partnership highlights the cost, integration, and ownership trade-offs in clinical BCIs.

Encora has secured FDA clearance for its wrist-worn X1 device for essential tremor. The decision adds a new entrant to the growing external upper limb tremor stimulator category.

Apple’s $1.6–2B Q.ai acquisition centers on silent speech. Its patents extend to facial micromovement sensing and physiological proxies, raising neuro-adjacent questions.

CraniUS raised $20m to advance NeuroPASS, a skull-embedded drug delivery system. The platform tests whether chronic access can make convection-enhanced delivery viable in routine care.

Brain health entered Davos as an economic priority, framed through Brain Capital and prevention. The analysis examines where policy ambition now outpaces biological evidence and measurement readiness.

A new open ECoG dataset highlights why long-term stability, not first implants, is becoming a key constraint in BCIs. Longevity reframes how progress and clinical value are judged.

Neurolief’s Proliv Rx receives FDA Premarket Approval for depression, marking a rare Class III clearance for a home-use neuromodulation device and following closely after Flow’s FDA entry.

Merge Labs launches with $250M in funding to pursue non-implant, ultrasound-based BCIs. The move contrasts with capital clustering around invasive platforms and reframes where early BCI risk is being underwritten.

Precision Neuroscience’s partnership with Medtronic embeds cortical interfaces into surgical navigation. The move highlights workflow integration as a pragmatic commercialization path for BCIs.

BrainCo’s $280m round places a non-implant EEG company among the most highly funded BCIs. The case highlights how China enables scale before markets fully mature and what that means for global competition.

Neurable has momentum, with new consumer EEG products, a $35m Series A, and a CES gaming prototype. The key question is whether EEG headphones can become a lasting daily habit rather than a novelty.

The UK is aligning ARIA funding, Cambridge NeuroWorks, and NHS reforms to advance non-invasive neurotech, closing the early-stage innovation gap and using national health infrastructure to validate and scale wearables.

Nia Therapeutics reports large-animal validation of its closed-loop neuromodulation system for memory disorders, supporting plans for first-in-human studies and highlighting a network-level approach to memory restoration.

The FDA has approved Flow Neuroscience’s FL-100, the first prescription at-home brain-stimulation device for major depressive disorder, bringing supervised tDCS into US clinical care.

ARPA-H has launched EVIDENT, a $100M program to build quantitative measurement systems and data infrastructure for mental health, linking rapid-acting treatments to objective, longitudinal clinical evidence.

Beacon Biosignals secured $86M in Series B funding and expanded its Takeda collaboration, positioning at-home EEG and sleep data as a scalable biomarker layer inside CNS drug development.

INBRAIN has teamed up with Microsoft to combine graphene BCIs with agentic AI on Azure, aiming to build adaptive, closed-loop neurotherapies that learn from each patient’s brain signals in real time.

NextSense has raised a $16M Series A to commercialize in-ear EEG Smartbuds, bringing direct brain-based sleep tracking and adaptive audio into a familiar consumer earbud form factor.

UNESCO has adopted the first global neurotechnology ethics standard, treating neural data as sensitive, banning sleep-based manipulation, and setting strict limits for workplace and classroom use as neurotech enters consumer products.

Nike’s new Mind shoes apply sensory stimulation through the foot to influence focus, signaling a major consumer brand’s entry into neuro-influenced product design.

Neuralink’s first UK implant shows its intracortical BCI can be deployed inside the NHS with rapid, functional control.

The PRIMA retinal implant demonstrates clinically validated restoration of functional vision in advanced macular degeneration, marking a major milestone for sensory BCIs.

Alto Neuroscience has raised $50 million and aligned with the FDA to accelerate its depression program, positioning biomarker-guided patient selection as a practical tool for late-stage psychiatric drug development.

A university hospital in Munich has completed Europe’s first intracortical BCI implant in a patient with quadriplegia, reflecting a clinic-first model focused on safety, rehabilitation, and healthcare-system readiness rather than speed or publicity.

Neuralink has leased a large life-science facility in South San Francisco, signaling a renewed Bay Area presence as the company moves from early human trials toward clinical scale-up and operational maturity.

As neurotechnology moves into consumer markets, U.S. lawmakers are proposing new protections for brain-derived data, signaling a shift in how neural signals are treated under privacy law.

Neural interfaces are moving from labs into consumer devices. With a wrist-worn EMG band, Meta is testing whether neural intent can become a practical input layer for everyday digital interaction.